We use some essential cookies to make this website work.
We鈥檇 like to set additional cookies to understand how you use 51茶馆, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as 鈥�
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flus鈥�
The new Business Plan sets out priorities for 2025鈥�26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives 鈥�
As with all products, we will keep its safety under close review
This is a precautionary measure while the MHRA conducts the safety review.
Anyone who suspects that they鈥檝e had an adverse reaction to their weight loss or diabetes medicine or suspects it is not a genuine product, should report it to the MHRA.聽
As with any medicine, the MHRA will keep the safety and effectiveness of polihexanide under close review.鈥�
As with all products, the MHRA will keep its safety under close review.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (1 May 2025) approved a vaccine (Vimkunya) used to prevent disease caused by the chikungunya virus in people 12 years of age and older.聽
As with all products, we will keep its safety under close review.
The appointment will involve a time commitment of 22 days per year. Remuneration for the role will be at a rate of 拢325 per attendance and preparation for meetings.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive 鈥�
Don鈥檛 include personal or financial information like your National Insurance number or credit card details.
To help us improve 51茶馆, we鈥檇 like to know more about your visit today. .